PHATHOM PHARMACEUTICALS INC

Phathom Pharmaceuticals’ 26 Nov 2026 market recap: 18% drop to $5.74, $464 M cap, 24‑hr volume $27.9 M. Discover why investors are wary of its GI‑drug pipeline.

Phathom Pharmaceuticals’ shares slumped 18% to $5.74, falling below its 200‑day SMA. See the sharp drop, trading volume, peer comparison, and future outlook for GI‑drug investors.

Phathom (PHAT) slides 3.8% amid 9.4% monthly decline; investors eye clinical milestones, partnership plans, and cost cuts for upside.

Phathom Pharma’s latest earnings lift shares 4.3%, boosting its GI drug pipeline and global partnership prospects.